Therefore, great efforts are now aimed at pharmacologically inhibiting ALK activity in NB cells by taking advantage of small molecule inhibitors such as crizotinib, an FDA-approved anticancer drug that exhibited efficacy in non-small cell lung cancers harboring ALK translocations [19]. The gene discussed is ALK; the disease is neuroblastoma.